Clinic of Ophthalmology, Campus Virchow Klinikum, Charité - University School of Medicine Berlin, Berlin, Germany.
Ophthalmologica. 2010;224(1):38-41. doi: 10.1159/000233237. Epub 2009 Aug 12.
To evaluate the efficacy and safety of topically applied mycophenolate mofetil (MMF) for the prophylaxis of corneal graft rejection in an experimental keratoplasty model.
A total of 12 female Lewis rats received 3.5-mm MHC I/II-incompatible corneal grafts from DA donors. Recipients were randomly assigned to receive either topical MMF + beta-cyclodextrin therapy (1%), beta-cyclodextrin therapy alone or to remain untreated. Therapy was applied every 2 h (over 24 h) during the first 3 postoperative days, then twice hourly during daytime. Grafts were graded every day based on a rejection score including the parameters transplant clarity and edema.
The mean survival time (MST) of the grafts in the MMF-treated group was 12 days, the MST in the vehicle-treated group was 14.3 days and the MST in the untreated group was 13.3 days. So, the survival curves of the 3 treatment groups did not differ significantly.
Topical MMF is ineffective for prophylaxis of corneal graft rejection.
评估局部应用霉酚酸酯（MMF）预防角膜移植排斥反应的疗效和安全性，建立实验性角膜移植模型。
12 只雌性 Lewis 大鼠接受 3.5mm MHC I/II 不相容供体 DA 的角膜移植。受者随机分为局部应用 MMF+β-环糊精治疗（1%）、β-环糊精治疗或不治疗。术后第 1 天至第 3 天，每 2 小时（24 小时内）用药 1 次，然后白天每小时用药 1 次。根据包括移植透明度和水肿在内的排斥评分标准，每天对移植物进行评分。
MMF 治疗组移植物的平均存活时间（MST）为 12 天，载体治疗组为 14.3 天，未治疗组为 13.3 天。因此，3 组治疗的生存曲线无显著差异。
局部应用 MMF 不能预防角膜移植排斥反应。
